Rose Hayeshi

Dr. Rose Hayeshi

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RHRose Hayeshi
Rose Hayeshi
Constanze HilgendorfConstanze Hilgendorf
Constanze Hilgendorf
PAPer Artursson
Per Artursson
PAPatrick Augustijns
Patrick Augustijns
BBBirger Brodin
Birger Brodin
AUAnna-Lena Ungell
Anna-Lena Ungell

1 December 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ECEsther H Chang
Esther H Chang
JHJoe B. Harford
Joe B. Harford
MEMichael A.W. Eaton
Michael A.W. Eaton
PBPatrick M. Boisseau
Patrick M. Boisseau
ADADMIRE DUBE
ADMIRE DUBE
DLDong Soo Lee
Dong Soo Lee

1 February 2007 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
RHRose Hayeshi
Rose Hayeshi
IMIsaac Mutingwende
Isaac Mutingwende
WMWilliam Mavengere
William Mavengere
VMVimbai Masiyanise
Vimbai Masiyanise
SMStanley Mukanganyama
Stanley Mukanganyama

1 September 2006 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RHRose Hayeshi
Rose Hayeshi
CMCollen Masimirembwa
Collen Masimirembwa
SMStanley Mukanganyama
Stanley Mukanganyama
AUAnna-Lena B. Ungell
Anna-Lena B. Ungell

24 November 2022 in Medicine in Drug Discovery
Verified
Journal Article
Open access
Ambrose OkemAmbrose Okem
Ambrose Okem
CHCharlotte Henstra
Charlotte Henstra
MLMaarten Lambert
Maarten Lambert
RHRose Hayeshi
Rose Hayeshi

10 June 2016 in Molecules
Verified
Journal Article
Open access
PDF file
CRClinton Rambanapasi
Clinton Rambanapasi
JZJan Rijn Zeevaart
Jan Rijn Zeevaart
HBHylton Buntting
Hylton Buntting
CBCornelius Bester
Cornelius Bester
DKDeon Kotze
Deon Kotze
AGAnne Grobler
Anne Grobler
Colloidal suspensions of 14 nm gold nanoparticles (AuNPs) were repeatedly administered intravenously at three dose levels (0.9, 9 and 90 µg) to male Sprague Dawley rats weekly for 7 weeks, followed by a 14-day washout period. After sacrificing, the amount of gold was quantified in the liver, lungs, spleen, skeleton and carcass using neutron activation analysis (NAA). During the study, pre- and post (24 h) administration blood samples were collected from both the test and control groups, the latter which received an equal injection volume of normal saline. General health indicators were monitored together with markers of kidney and liver damage for acute and subchronic toxicity assessment. Histopathological assessments were done on the heart, kidneys, liver, lungs and spleen to assess any morphological changes as a result of the exposure to AuNPs. The mass measurements of all the groups showed a steady increase with no signs of overt toxicity. The liver had the highest amount of gold (µg) per gram of tissue after 56 days followed by the spleen, lungs, skeleton and carcass. Markers of kidney and liver damage showed similar trends between the pre and post samples within each group and across groups. The histopathological examination also showed no hepatotoxicity and nephrotoxicity. There was accumulation of Au in tissues after repeated dosing, albeit with no observable overt toxicity, kidney or liver damage.